Research progress of furmonertinib for EGFR-mutated non-small cell lung cancer / 中国药房
China Pharmacy
;
(12): 1788-1792, 2023.
Artigo
em Chinês
| WPRIM
| ID: wpr-978976
ABSTRACT
Lung cancer is mainly non-small cell lung cancer (NSCLC). NSCLC is often associated with epidermal growth factor receptor (EGFR) gene mutations. Currently, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) are the preferred first-line treatment option for EGFR-mutated NSCLC. Furmonertinib is the second third-generation EGFR-TKI marketed in China, which is developed independently by China. In this review, it is found that furmonertinib has dual activity, strong tumor suppression, high selectivity, and high safety profile, and is effective in the treatment of EGFR-sensitive mutation, EGFR exon 20 T790M resistance mutation, EGFR exon 20 insertion mutation, and central nervous system metastasis NSCLC, and its relevant clinical trials are only enrolled in Chinese patients, which is more guidance for Chinese NSCLC patients in China.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
China Pharmacy
Ano de publicação:
2023
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS